Journal
JOURNAL OF HYPERTENSION
Volume 20, Issue 1, Pages 3-9Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00004872-200201000-00002
Keywords
sympathetic nervous system; blood pressure; renal afferents; angiotensin II
Categories
Funding
- NHLBI NIH HHS [HL 07360] Funding Source: Medline
- NIDDK NIH HHS [K24 DK 30487] Funding Source: Medline
Ask authors/readers for more resources
Objective To review the current literature on sympathetic mediation of hypertension in chronic renal failure. Background Hypertension is present in the vast majority of patients with chronic renal failure and constitutes a major risk factor for the excessive cardiovascular morbidity and mortality in this patient population. Although, traditionally, this hypertension is thought to be largely volume-dependent, an increasing body of literature suggests that there is an important sympathetic neural component. Microneurographic studies have demonstrated sympathetic overactivity without baroreflex impairment in both hypertensive chronic hemodialysis patients as well as in those with less advanced renal insufficiency. Sympathetic nerve activity was found to be normal in hemodialysis patients with bilateral nephrectomy, leading to the hypothesis that sympathetic overactivity in uremia is caused by a neurogenic signal (carried by renal afferents) arising in the failing kidney. This hypothesis is supported by rat studies showing that renal deafferentation abrogates hypertension in the 5/6 nephrectomy model of chronic renal insufficiency. In addition, in patients with chronic renal insufficiency and resin-dependent hypertension, sympathetic overactivity was normalized by chronic angiotensin converting enzyme inhibition but not by calcium channel blockade, implicating a major central neural action of angiotensin II. Conclusions Sympathetic overactivity in chronic renal failure is caused by neurohormonal mechanisms arising in the failing kidney. Future clinical studies are needed to determine whether normalization of sympathetic activity should constitute an important therapeutic goal in this high-risk patient population. J Hypertens 20:3-9 (C) 2002 Lippincott Williams Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available